Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study (Q43623654)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study |
scientific article |
Statements
1 reference
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study (English)
1 reference
Marek Hartleb
Pol F Boudes
Mark G Swain
Christopher L Bowlus
Michael R Galambos
Bruce R Bacon
Yvonne Doerffel
Norman Gitlin
Stuart C Gordon
Joseph A Odin
Markus-Alexander Wörns
Virginia Clark
Heinz Hartmann
Mark E Jonas
Andreas E Kremer
George F Mells
Peter Buggisch
Bradley L Freilich
Cynthia Levy
John M Vierling
David E Bernstein
Fedja Rochling
Hemant Shah
Mitchell L Shiffman
John H Smith
Yun-Jung Choi
Alexandra Steinberg
Monika Varga
Harinder Chera
Robert Martin
Charles A McWherter
14 August 2017
1 reference